Kanglong Wang

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism.

Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism.

Journal: Cell metabolism
Published: July 22, 2026

Dietary fat alters goblet cell function and microbial bile acid metabolism to promote intestinal lipid absorption in mice.

Dietary fat alters goblet cell function and microbial bile acid metabolism to promote intestinal lipid absorption in mice.

Journal: Nature microbiology
Published: July 29, 2025

Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD.

Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD.

Journal: Cell reports. Medicine
Published: April 14, 2025

Lipidomics reveals potential biomarkers and pathophysiological insights in the progression of diabetic kidney disease.

Lipidomics reveals potential biomarkers and pathophysiological insights in the progression of diabetic kidney disease.

Journal: Metabolism open
Published: January 14, 2025

Glycyrrhizic acid and patchouli alcohol in Huoxiang Zhengqi attenuate intestinal inflammation and barrier injury via regulating endogenous corticosterone metabolism mediated by 11β-HSD1.

Glycyrrhizic acid and patchouli alcohol in Huoxiang Zhengqi attenuate intestinal inflammation and barrier injury via regulating endogenous corticosterone metabolism mediated by 11β-HSD1.

Journal: Journal of ethnopharmacology
Published: August 16, 2024

Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism.

Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism.

Journal: Cell metabolism
Published: July 15, 2024

Correction: Limosilactobacillus reuteri and caffeoylquinic acid synergistically promote adipose browning and ameliorate obesity-associated disorders.

Correction: Limosilactobacillus reuteri and caffeoylquinic acid synergistically promote adipose browning and ameliorate obesity-associated disorders.

Journal: Microbiome
Published: August 14, 2023

Obesity induced disruption on diurnal rhythm of insulin sensitivity via gut microbiome-bile acid metabolism.

Obesity induced disruption on diurnal rhythm of insulin sensitivity via gut microbiome-bile acid metabolism.

Journal: Biochimica et biophysica acta. Molecular and cell biology of lipids
Published: July 18, 2023

Ootheca mantidis mitigates renal fibrosis in mice by the suppression of apoptosis via increasing the gut microbe Akkermansia muciniphila and modulating glutamine metabolism.

Ootheca mantidis mitigates renal fibrosis in mice by the suppression of apoptosis via increasing the gut microbe Akkermansia muciniphila and modulating glutamine metabolism.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 01, 2023

Development of a simultaneous quantification method for the gut microbiota-derived core nutrient metabolome in mice and its application in studying host-microbiota interaction.

Development of a simultaneous quantification method for the gut microbiota-derived core nutrient metabolome in mice and its application in studying host-microbiota interaction.

Journal: Analytica chimica acta
Published: December 06, 2022

Limosilactobacillus reuteri and caffeoylquinic acid synergistically promote adipose browning and ameliorate obesity-associated disorders.

Limosilactobacillus reuteri and caffeoylquinic acid synergistically promote adipose browning and ameliorate obesity-associated disorders.

Journal: Microbiome
Published: September 26, 2022

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.

Journal: Journal of medicinal chemistry
Published: September 15, 2022
Showing 1-12 of 14

Last Updated: 09/26/2026